293753-05-6

Basic information

• Product Name: SR3335
• Synonyms: SR3335;SR3335,Thiophene-2-sulfonic acid [4-(2,2,2-trifluoro-1-hydroxy-1-trifluoroMethyl-ethyl)-phenyl]-aMide;ML-176;N-[4-[2,2,2-Trifluoro-1-hydroxy-1-(trifluoromethyl)ethyl]phenyl]-2-thiophenesulfonamide;hiophene-2-sulfonic acid [4-(2,2,2-trifluoro-1-hydroxy-1-trifluoroMethyl-ethyl)-phenyl]-aMide
• CAS NO: 293753-05-6
• Molecular Formula: C₁₃H₉F₆NO₃S₂
• Molecular Weight: 405.3358792
• Mol File: 293753-05-6.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Inert atmosphere,Store in freezer, under -20°C
• Solubility: insoluble in H2O; ≥87.4 mg/mL in EtOH; ≥88.8 mg/mL in DMSO
• CAS DataBase Reference: SR3335(CAS DataBase Reference)
• NIST Chemistry Reference: SR3335(293753-05-6)
• EPA Substance Registry System: SR3335(293753-05-6)

Safety Data

• Hazardous Substances Data: 293753-05-6(Hazardous Substances Data)

Usage

Description

SR3335 is a selective inverse agonist of RORα, a type of orphan nuclear receptor. It competitively inhibits the binding of 25-hydroxycholesterol to the ligand binding domain and inhibits constitutive transactivation activity. SR3335 does not affect RORβ, RORγ, farnesoid X receptor, or liver X receptor α. It induces RORα-dependent effects both in vitro and in vivo, altering gene expression and gluconeogenesis.

Uses

Used in Pharmaceutical Industry:
SR3335 is used as a selective inverse agonist for RORα, targeting the treatment of various diseases by inhibiting the binding of 25-hydroxycholesterol and altering gene expression and gluconeogenesis.
Used in Research Applications:
SR3335 is used as a research tool for studying the role of RORα in various biological processes and for investigating the potential therapeutic effects of targeting this receptor in different diseases.

Upstream product

• 62-53-3 aniline 
• 16629-19-9 thiophene-2-sulfonyl chloride 
• 722-92-9 2-(4-aminophenyl)-1,1,1,3,3,3-hexafluoro-2-propanol 

Relevant articles and documents

Discovery and optimization of a series of sulfonamide inverse agonists for the retinoic acid receptor-related orphan receptor-α

Background: Despite a massive industry endeavor to develop RORγ-modulators for autoimmune disorders, there has been no indication of efforts to target the close family member RORα for similar indications. This may be due to the misconception that RORα is